NICE Recommends Zeposia for Certain Patients With Ulcerative Colitis

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Bristol Myers Squibb company Celgene’s Zeposia (ozanimod) for National Health Service (NHS) use in the treatment of adult patients with moderate-to-severe active ulcerative colitis.

Specifically, the recommendation is for patients who have had an inadequate response or were intolerant to either conventional therapy or a biologic agent.

The recommendation is based on a clinical trial showing the drug’s efficacy compared to placebo. However, there is no direct evidence comparing Zeposia with standard treatments that are offered after conventional treatment, said NICE in its report.

The recommended dose of Zeposia hard capsules is 0.92 mg. once daily following an initial dose escalation regimen from day one to day seven.

The list price for an induction pack of Zeposia is more than $393. The price of a maintenance pack of 28 capsules is more than $1,570. The negotiated price for NHS use was not disclosed.